Simcere Pharmaceutical Group Limited (FRA:S2P)

Germany flag Germany · Delayed Price · Currency is EUR
1.250
+0.030 (2.46%)
At close: Jan 30, 2026
48.81%
Market Cap3.26B +57.2%
Revenue (ttm)844.70M +12.1%
Net Income104.62M
EPS0.04
Shares Outn/a
PE Ratio31.13
Forward PE21.80
Dividend0.02 (1.57%)
Ex-Dividend DateJun 18, 2025
Volume500
Average Volume30
Open1.250
Previous Close1.220
Day's Range1.250 - 1.250
52-Week Range0.820 - 1.600
Betan/a
RSI45.40
Earnings DateMar 20, 2026

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW... [Read more]

Industry Pharmaceutical Preparations
Founded 1995
Employees 6,815
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol S2P
Full Company Profile

Financial Performance

In 2024, FRA:S2P's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY Financial Statements